Form 4: Alto Neuroscience CFO's Stock Options Repriced Amidst Share Price Decline

Alto Neuroscience, Inc. has repriced stock options for its Chief Financial Officer, Nicholas Conrad Smith, lowering the exercise price to $2.35 per share for over 500,000 options.

Summary

• Nicholas Conrad Smith, Chief Financial Officer and Chief Business Officer of Alto Neuroscience, Inc. (ANRO), reported changes in his beneficial ownership of derivative securities.
• The filing details a one-time stock option repricing (the "Option Repricing") effective July 3, 2025.
• The repricing applies to employee stock options with original exercise prices greater than $2.35 per share held by continuing employees as of the Repricing Date.
• The exercise price of the repriced options has been amended to $2.35 per share, which was the closing price of Alto Neuroscience's common stock on the Repricing Date.
• A total of 506,124 employee stock options held by Mr. Smith were affected by this repricing.
• The original exercise prices for these options ranged from $4.20 to $14.88 per share.
• A key condition of the repricing is that if an employee exercises a repriced option before the end of a one-year retention period (subject to earlier termination in certain circumstances), they will be required to pay the original exercise price per share.
• There are no changes to the vesting schedules, expiration dates, or the number of shares underlying the repriced options.
• The vesting schedules for the repriced options vary, with some vesting monthly, some quarterly, and some upon IPO completion, subject to continuous service.

Sentiment

Score: 3

Explanation: The repricing of stock options, while beneficial for employee retention and motivation, generally signals poor past stock performance and potential future dilution for shareholders. This is typically viewed as a negative event by the market, hence a low sentiment score.

Positives

• The repricing of stock options to a lower exercise price of $2.35 per share can serve as a renewed incentive for the Chief Financial Officer, potentially improving retention and motivation.
• The repricing aligns the incentive structure with the current market valuation of the company's stock, making the options more likely to be in-the-money and thus valuable to the employee.

Negatives

• Stock option repricing typically occurs when a company's share price has significantly declined, indicating poor past stock performance and potentially a lack of confidence in the near-term recovery to previous highs.
• The repricing could be perceived negatively by existing shareholders as it effectively grants new, lower-priced options, which can lead to increased dilution if exercised, without requiring the same level of stock price appreciation as the original options.
• The one-year retention period during which the original exercise price must be paid if options are exercised limits the immediate benefit to the employee and suggests a need to tie the employee to the company for a longer duration.

Risks

• Potential for shareholder dilution if the repriced options are exercised, increasing the number of outstanding shares.
• Negative market perception and investor sentiment due to the repricing, as it often signals that previously granted options were significantly underwater.
• Risk of employee dissatisfaction if the stock price does not recover sufficiently to make even the repriced options attractive, or if the retention period is seen as overly restrictive.

Future Outlook

The stock option repricing is intended to re-incentivize the Chief Financial Officer by making his equity awards more valuable at the current stock price. The one-year retention period for the repriced options aims to ensure continued service and alignment with long-term company performance before the full benefit of the repricing can be realized without penalty.

Management Comments

• The transactions reported herein reflect a one-time stock option repricing effective on July 3, 2025.
• The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date.
• Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date.
• If an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option.
• There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options.

Industry Context

Stock option repricing is a common practice in industries, particularly in biotechnology or high-growth sectors, where stock prices can be volatile. It is often employed when a company's stock price has significantly declined, rendering previously granted employee stock options 'underwater' (i.e., their exercise price is higher than the current market price), thereby diminishing their incentive value. Repricing aims to restore the motivational aspect of equity compensation and retain key talent.

Comparison to Industry Standards

• Stock option repricing is a known compensation tool, often used by companies like Alto Neuroscience in the biotech sector when stock performance lags, similar to practices seen in companies such as Biogen (BIIB) or Moderna (MRNA) during periods of significant stock price volatility or decline.
• The specific condition requiring payment of the original exercise price if options are exercised within a one-year retention period is a less common but not unheard-of feature, designed to mitigate immediate 'windfall' gains and ensure continued employee commitment, differentiating it from a 'clean' repricing where the new price is immediately effective.
• The repricing of options with original strike prices significantly above the current market price ($14.88 vs. $2.35) is indicative of a substantial decline in share value, a situation that has prompted similar repricing actions at other growth-oriented companies that have experienced significant post-IPO valuation adjustments.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for future dilution if repriced options are exercised, and a negative signal regarding past stock performance. May impact investor confidence.
• Employees (specifically the CFO): Increased incentive and retention due to more valuable equity awards, aligning their financial interests more closely with the current stock price.

Next Steps

• Continued vesting of the repriced stock options according to their original schedules.
• Potential exercise of the repriced options by the Chief Financial Officer, subject to the one-year retention period condition.

Key Dates

Recommendation

Keywords

SEC Form 4, Stock Option Repricing, Executive Compensation, Insider Transaction, Alto Neuroscience, ANRO, Nicholas Conrad Smith, CFO, Employee Stock Option, Beneficial Ownership